We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.25 | -6.41% | 18.25 | 18.00 | 18.50 | 19.75 | 18.25 | 19.75 | 474,539 | 08:43:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.34 | 50.81M |
From Nov 2023 to May 2024
By Ian Walker
Angle PLC shares rose as much as 41% in early trade after the company said that DNA molecular analysis from cancer patient blood samples provides insight into the progression and treatment of cancers for those patients, and enables it to expand product sales and pharmaceutical service offerings.
Shares at 0834 GMT were up 4.50 pence, or 34%, at 17.75 pence having peaked at 18.63 pence earlier in the session. However, they are down 63% over the past 12 months.
The U.K. liquid-biopsy company said Thursday that the results come from 47 patient samples in breast, lung, prostate and ovarian cancers.
"Today's breakthrough is the critical next step post the [Food and Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of NGS [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples," Chief Executive Officer Andrew Newland said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 04, 2024 03:55 ET (08:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
